UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
World Genetics And Genomics Online Conference, 17-19 May 2012
Date: May-02-2012Target Meeting is a leading online life science conference organizer. They specialize in organizing conferences, symposiums and workshops, which brings together the known researchers, professors and life science suppliers from across the world to debate over the latest developments in biomedical research. The 2012 World Genetics & Genomics Online Conference scheduled to be held on May 17 - 19, 2012. The 12 sessions, which will be spread over three days will discuss Statistical genetics, Molecular genetics, Genetic regulation, Genomics development, Microarray and bioinformatics, Chromosome and...
Spotting Breast Cancer Risk Years Before It Occurs
Date: May-02-2012Scientists from Imperial College London say that women with very high levels of methylation in an area of a gene, known as ATM, had double the risk of going on to develop breast cancer, compared to those without the faulty gene. Their study, which has been published in the journal Cancer Research, found that a woman's risk of breast cancer may be decided several years before the disease develops. Dr James Flanagan say he has uncovered compelling evidence that "epigenetic" gene changes may be linked with breast cancer risk. Flanagan and team examined 640 women with breast cancer and 741 women...
Nanotechnology That May Enhance Medication Delivery And Improve MRI Performance
Date: May-02-2012Researchers at Harvard-affiliated McLean Hospital have shown a new category of "green" nanoparticles comprised of a non-toxic, protein-based nanotechnology that can non-invasively cross the blood brain barrier and is capable of transporting various types of drugs. In an article published online in PLoS ONE, Gordana Vitaliano, MD, director of the Brain Imaging NaNoTechnology Group at the McLean Hospital Imaging Center, reported that clathrin protein, a ubiquitous protein found in human, animal, plant, bacteria and fungi cells, has been modified for use as a nanoparticle for in-vivo studies....
Researchers Identify Drivers Of Sarcoma Growth And Survival
Date: May-02-2012To better understand the signaling pathways active in sarcomas, researchers at Moffitt Cancer Center used state-of-the-art mass spectrometry-based proteomics to characterize a family of protein enzymes that act as "on" or "off" switches important in the biology of cancer. The tyrosine kinases they identified, the researchers said, could act as "drivers" for the growth and survival of sarcomas. Sarcomas are relatively rare forms of cancer. In contrast to carcinomas, which arise from epithelial cells (in breast, colon and lung cancers, for example), sarcomas are tumors derived from bone, fat,...
Interpreting The Avastin-Lucentis Study For Persons With Macular Degeneration
Date: May-02-2012This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology. Researchers found that two drugs known as Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat the wet form of AMD, were similarly effective in maintaining vision. In this clinical trial funded by the National Eye Institute (NEI) of the National Institutes of Health, CATT researchers found that two years into the study, two-thirds of patients retained a vision of...
Interferon For Hepatitis C Can Cause Depression
Date: May-02-2012There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression. In a review article, researchers tackle the complexities of diagnosing and managing depression before and after initiating treatment with interferon. Dr. Murali S. Rao of Loyola University Medical Center is a co-author of the study, published in the International Journal of Interferon, Cytokine and Mediator Research. "Depression is a relatively frequent and potentially serious complication of interferon therapy for hepatitis C virus...
PTSD Symptoms May Be Relieved By Some Blood Pressure Drugs
Date: May-02-2012Traumatized people who take a class of common blood pressure medications tend to have less severe post-traumatic stress symptoms, researchers have found. The finding suggests that ACE (angiotensin converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) could be valuable tools for treating or preventing post-traumatic stress disorder. The results were published online in the Journal of Clinical Psychiatry. "These results are particularly exciting because it's the first time ACE inhibitors and ARBs have been connected to PTSD, and it gives us a new direction to build on," says...
Family-Based Treatment For Childhood Obesity
Date: May-02-2012With nearly one-third of American children being overweight or obese, doctors agree that there is an acute need for more effective treatments. In many weight management programs, the dropout rate can be as high as 73 percent, and even in successful programs, the benefits are usually short term. Although family-based approaches to pediatric obesity are considered the gold standard of treatment, theories of the family and how it functions have not been incorporated into effective interventions, according to a study published in the May issue of the International Journal of Obesity by researchers...
Low Cost, Lifesaving Services Missing From Most Older Patients' Health Care: National Poll
Date: May-02-2012Large majorities of older Americans experience significant and troubling gaps in their primary care, according to a new national survey, "How Does It Feel? The Older Adult Health Care Experience," released by the John A. Hartford Foundation, a champion for improved geriatric care and longtime partner of the Hartford Institute for Geriatric Nursing at New York University's College of Nursing. The poll focuses exclusively on Americans age 65 and older and assesses whether, in the past 12 months, patients received seven important medical services to support healthy aging, including: an annual...
Pulmonary Arterial Hypertension - Phase III SERAPHIN Outcome Study Meets Primary Endpoint
Date: May-02-2012The initial analysis of Actelion's macitentan, a novel dual endothelin receptor antagonist that resulted from a tailored drug discovery process, has met its primary endpoint in a pivotal, long term, event-driven SERAPHIN Phase III trial. SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) was the largest randomized, controlled study in pulmonary arterial hypertension patients with a long-term treatment, designed to evaluate the efficacy and safety of macitentan, which includes a clearly defined morbidity/mortality primary...
Stay Connected
